← Back to Search

Imaging Comparison for Age-Related Macular Degeneration (COCO-GA Trial)

N/A
Recruiting
Led By Amitha Domalpally, MD, PhD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 75 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial compares imaging devices to determine which is most accurate at measuring vision loss caused by GA. Patients with GA may join to help improve diagnosis standards.

Who is the study for?
This trial is for individuals over 50 with a specific eye condition called geographic atrophy due to age-related macular degeneration. Participants should have GA areas between 1.25 and 23 mm², which can be either subfoveal or extrafoveal. Those with neovascular AMD, other retinal diseases that could affect the study, or who cannot undergo eye imaging are not eligible.
What is being tested?
The trial aims to compare three different eye imaging systems: Spectralis FAF, Optos, and Zeiss Clarus 700. It will determine which system's measurements of geographic atrophy area align most closely with the standard care device in patients visiting University Station Eye Clinic.
What are the potential side effects?
Since this study involves non-invasive imaging techniques rather than medication or surgery, side effects are minimal but may include discomfort from bright lights during imaging or temporary visual disturbances after the procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 75 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 75 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Comparison of geographic atrophy area measurements between Clarus and Optos
Comparison of geographic atrophy area measurements by Clarus with standard Spectralis imaging
Comparison of geographic atrophy area measurements by Optos with standard Spectralis imaging
Secondary study objectives
Prevalence of atrophy outside the standard 30 degrees in Clarus and Optos ultrawide field images
Prevalence of other autofluorescence abnormalities outside the standard 30 degrees in Clarus and Optos ultrawide field images

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Fundus autofluorescence (FAF) imagingExperimental Treatment3 Interventions

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,237 Previous Clinical Trials
3,200,929 Total Patients Enrolled
4 Trials studying Macular Degeneration
6,377 Patients Enrolled for Macular Degeneration
Amitha Domalpally, MD, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison

Media Library

Fundus autofluorescence (FAF) imaging Clinical Trial Eligibility Overview. Trial Name: NCT05961332 — N/A
Macular Degeneration Research Study Groups: Fundus autofluorescence (FAF) imaging
Macular Degeneration Clinical Trial 2023: Fundus autofluorescence (FAF) imaging Highlights & Side Effects. Trial Name: NCT05961332 — N/A
Fundus autofluorescence (FAF) imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT05961332 — N/A
~6 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top